{
  "url": "https://allermi-site.vercel.app/compare/nasacort-vs-rhinocort/",
  "collection": "compare",
  "slug": "nasacort-vs-rhinocort",
  "frontmatter": {
    "title": "Nasacort vs Rhinocort: For Pregnancy or Kids",
    "description": "Triamcinolone vs budesonide: why Rhinocort wins pregnancy and where Nasacort still fits.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "nasacort vs rhinocort",
    "ymylTier": "high",
    "citations": [],
    "tldr": "Rhinocort (budesonide) is pregnancy first-line, the most extensive and reassuring pregnancy data of any INCS. Nasacort (triamcinolone) has a small first-trimester oral-cleft signal and is generally avoided in pregnancy. Outside pregnancy, both are effective OTC steroids; Nasacort is 2+, Rhinocort 6+.",
    "claims": [
      "c-026",
      "c-027",
      "c-028",
      "c-029",
      "c-034",
      "c-055"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Rhinocort = pregnancy first-line",
        "tier": "guideline"
      },
      {
        "text": "Avoid Nasacort in pregnancy (oral-cleft signal)",
        "tier": "cohort"
      },
      {
        "text": "Nasacort 2+, Rhinocort 6+ for OTC age indication",
        "tier": "fda-label"
      }
    ],
    "related": [
      {
        "href": "/reviews/nasacort/",
        "label": "Nasacort review",
        "kind": "Product",
        "description": "OTC triamcinolone, ages 2+."
      },
      {
        "href": "/reviews/rhinocort/",
        "label": "Rhinocort review",
        "kind": "Product",
        "description": "OTC budesonide, pregnancy first-line INCS."
      },
      {
        "href": "/compare/flonase-vs-nasacort/",
        "label": "Flonase vs Nasacort",
        "kind": "Head-to-head",
        "description": "The broader OTC steroid picks."
      },
      {
        "href": "/compare/flonase-vs-rhinocort/",
        "label": "Flonase vs Rhinocort",
        "kind": "Head-to-head",
        "description": "Fluticasone alternative for pregnancy backup."
      },
      {
        "href": "/compare/rhinocort-vs-nasonex/",
        "label": "Rhinocort vs Nasonex",
        "kind": "Head-to-head",
        "description": "Budesonide vs mometasone: both acceptable in pregnancy."
      },
      {
        "href": "/demographic/pregnancy/",
        "label": "Safe nasal sprays in pregnancy",
        "kind": "Demographic",
        "description": "Trimester × product safety matrix."
      },
      {
        "href": "/demographic/kids/",
        "label": "Nasal sprays for kids",
        "kind": "Demographic",
        "description": "Ages 2–3 need Nasacort or Sensimist; Rhinocort is 6+."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Either INCS works outside pregnancy."
      }
    ],
    "subjects": [
      {
        "id": "nasacort",
        "name": "Nasacort 24HR"
      },
      {
        "id": "rhinocort",
        "name": "Rhinocort Allergy"
      }
    ]
  },
  "outline": [
    {
      "id": "winner-in-context-allermi-is-our-1-for-eligible-adults",
      "text": "Winner in context: Allermi is our #1 for eligible adults",
      "children": []
    },
    {
      "id": "which-to-pick",
      "text": "Which to pick",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 2,
    "guideline": 0,
    "fdaLabel": 4,
    "cohort": 0,
    "expert": 0
  },
  "claimIds": [
    "c-026",
    "c-027",
    "c-028",
    "c-029",
    "c-034",
    "c-055"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport AllermiPickCallout from '../../components/AllermiPickCallout.astro';\n\n<AllermiPickCallout\n variant=\"prominent\"\n title=\"Our overall #1 pick for eligible adults: Allermi\"\n body=\"This matchup is dominated by pregnancy: Rhinocort is first-line, Nasacort is generally avoided. If you are an eligible patient 13+ who is not pregnant or breastfeeding, our overall pick is Allermi: a compounded, allergist-designed nasal spray that personalizes a steroid plus azelastine plus ipratropium plus a micro-dose of oxymetazoline in one bottle.\"\n cta=\"Check your eligibility for Allermi\"\n liabilityNote=\"Not a fit for pregnancy or breastfeeding. If pregnant, Rhinocort is the pick; check allermi.com/pages/eligibility for post-pregnancy.\"\n/>\n\n<Claim id=\"c-026\">The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy.</Claim> <Claim id=\"c-055\">A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts.</Claim> <Claim id=\"c-027\">A 2007 NBDPS analysis identified a small association between first-trimester triamcinolone exposure and oral clefts.</Claim> <Claim id=\"c-028\">Nasacort is generally avoided in pregnancy due to the oral-cleft signal.</Claim> <Claim id=\"c-029\">Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older</Claim> <Claim id=\"c-034\">Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older</Claim>\n\n## Winner in context: Allermi is our #1 for eligible adults\n\nFor eligible patients 13+ (not pregnant, not breastfeeding), [Allermi](/reviews/allermi/) is our overall pick. Personalized multi-active therapy in one bottle beats either single-ingredient OTC steroid. Rhinocort stays first-line in pregnancy, and Nasacort keeps its niche for ages 2–5.\n\n## Which to pick\n\n[Pregnancy](/demographic/pregnancy/) → [Rhinocort](/reviews/rhinocort/). Toddlers ages 2–5 → [Nasacort](/reviews/nasacort/) (Rhinocort is 6+; see also [kids page](/demographic/kids/)). Outside those two scenarios, either works for [chronic allergic congestion](/symptom/congestion/), and [Flonase](/reviews/flonase/) is a third comparable pick with unique FDA eye-symptom coverage.\n\n<AllermiPickCallout\n title=\"Not sold on either Nasacort or Rhinocort? Allermi outperforms both for eligible adults.\"\n body=\"Allergist-designed personalized compound, one bottle. Patients 13+ only.\"\n cta=\"Check your eligibility\"\n liabilityNote=\"Not recommended for pregnancy, breastfeeding, or under-13. In pregnancy, Rhinocort is first-line.\"\n/>\n\n<CitationList items={[\n { id: \"1\", title: \"MotherToBaby: Budesonide\", url: \"https://mothertobaby.org/fact-sheets/budesonide/\", publisher: \"OTIS\" },\n { id: \"2\", title: \"MotherToBaby: Triamcinolone\", url: \"https://mothertobaby.org/fact-sheets/triamcinolone/\", publisher: \"OTIS\" }\n]} />",
  "claims": [
    {
      "id": "c-026",
      "claim": "The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/12704351/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "Dr. Nguyen",
      "qualifiers_required": [
        "inhaled",
        "frequently choose",
        "extrapolation"
      ]
    },
    {
      "id": "c-027",
      "claim": "Triamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label also notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasacort"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-028",
      "claim": "It is not established that intranasal triamcinolone causes cleft palate or other malformations in humans when used as directed; clinicians frequently default to Rhinocort (budesonide) in pregnancy because budesonide has a more extensive pregnancy-specific human dataset",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasacort"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "Dr. Nguyen"
    },
    {
      "id": "c-029",
      "claim": "Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bff57a5-cce0-401c-a0fe-23c65c1b7ddc",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasacort"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-034",
      "claim": "Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffca32a2-fbef-40bb-b0f0-73f63e18e747",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-055",
      "claim": "A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/10074986/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "hard"
    }
  ]
}